Iterum Therapeutics Reports Third Quarter 2022 Financial Results
–Patient Enrollment in Registration Trial for uUTI Underway–
–Cash Runway into 2024–
DUBLIN, Ireland and CHICAGO, Nov. 10, 2022 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq:ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2022.
Related news for (ITRM)
- Breaking News: MoBot’s Latest Update as of 04/23/25 03:00 PM
- The MoBot Report
- Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
- Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
- Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023